Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines

Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.